{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:12:20Z","timestamp":1791223940743,"version":"4.1.0"},"reference-count":31,"publisher":"Becaris Publishing Limited","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2020,3]]},"abstract":"<jats:p><jats:bold>Aim:<\/jats:bold>Ozanimod and fingolimod are sphingosine 1-phosphate receptor\u2013modulating therapies for relapsing multiple sclerosis.<jats:bold>Patients &amp; methods:<\/jats:bold>Comparative effectiveness was assessed by matching adjusted indirect comparisons of safety and efficacy trial outcomes at first-dose cardiac monitoring, 1\u00a0year and 2\u00a0years.<jats:bold>Results:<\/jats:bold>After adjustment, baseline characteristics were similar. Ozanimod was associated with a lower risk of extended first-dose monitoring, conduction abnormalities including atrioventricular block. One-year risks of any adverse event (AE), mean lymphocyte count reductions and abnormal liver enzymes were lower with ozanimod. Two-year risks of AEs leading to discontinuation, any AEs, herpetic infections, bradycardia and abnormal liver enzymes were lower with ozanimod. Analyses of efficacy outcomes were similar.<jats:bold>Conclusion:<\/jats:bold>Ozanimod appears to have a favorable benefit-risk profile versus fingolimod.<\/jats:p>","DOI":"10.2217\/cer-2019-0169","type":"journal-article","created":{"date-parts":[[2020,1,17]],"date-time":"2020-01-17T09:12:56Z","timestamp":1579252376000},"page":"275-285","source":"Crossref","is-referenced-by-count":42,"title":["Comparative safety and efficacy of ozanimod versus fingolimod for relapsing multiple sclerosis"],"prefix":"10.57264","volume":"9","author":[{"given":"Elyse","family":"Swallow","sequence":"first","affiliation":[{"name":"Analysis Group, Inc., 111 Huntington Avenue, 14th Floor, Boston, MA 02199, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Patterson-Lomba","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc., 111 Huntington Avenue, 14th Floor, Boston, MA 02199, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Yin","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc., 111 Huntington Avenue, 14th Floor, Boston, MA 02199, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rina","family":"Mehta","sequence":"additional","affiliation":[{"name":"US HEOR, Bristol-Myers Squibb, 86 Morris Avenue, Summit, NJ 07901, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey","family":"Pelletier","sequence":"additional","affiliation":[{"name":"US HEOR, Bristol-Myers Squibb, 86 Morris Avenue, Summit, NJ 07901, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kao","sequence":"additional","affiliation":[{"name":"US HEOR, Bristol-Myers Squibb, 86 Morris Avenue, Summit, NJ 07901, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James K","family":"Sheffield","sequence":"additional","affiliation":[{"name":"US HEOR, Bristol-Myers Squibb, 86 Morris Avenue, Summit, NJ 07901, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Stonehouse","sequence":"additional","affiliation":[{"name":"US HEOR, Bristol-Myers Squibb, 86 Morris Avenue, Summit, NJ 07901, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Signorovitch","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc., 111 Huntington Avenue, 14th Floor, Boston, MA 02199, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"issue":"3","key":"e_1_3_7_3_2","doi-asserted-by":"crossref","first-page":"e446","DOI":"10.1212\/NXI.0000000000000446","article-title":"Treatment choices and neuropsychological symptoms of a large cohort of early MS","volume":"5","author":"Von Bismarck O","year":"2018","unstructured":"Von Bismarck O , Dankowski T , Ambrosius B Treatment choices and neuropsychological symptoms of a large cohort of early MS. Neurol. Neuroimmunol. Neuroinflamm. 5(3), e446 (2018).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"5","key":"e_1_3_7_4_2","doi-asserted-by":"crossref","first-page":"e279","DOI":"10.1212\/NXI.0000000000000279","article-title":"The topographical model of multiple sclerosis: a dynamic visualization of disease course","volume":"3","author":"Krieger SC","year":"2016","unstructured":"Krieger SC , Cook K , De Nino S , Fletcher M . The topographical model of multiple sclerosis: a dynamic visualization of disease course. Neurol. Neuroimmunol. Neuroinflamm. 3(5), e279 (2016).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"3","key":"e_1_3_7_5_2","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","article-title":"Defining the clinical course of multiple sclerosis: the 2013 revisions","volume":"83","author":"Lublin FD","year":"2014","unstructured":"Lublin FD , Reingold SC , Cohen JA Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 83(3), 278\u2013286 (2014).","journal-title":"Neurology"},{"key":"e_1_3_7_6_2","unstructured":"Olek M Howard J . Clinical presentation course and prognosis of multiple sclerosis in adults. https:\/\/www.uptodate.com\/contents\/clinical-presentation-course-and-prognosis-of-multiple-sclerosis-in-adults"},{"key":"e_1_3_7_7_2","unstructured":"European Medicines Agency. Guideline on clinical investigation of medicinal products for the treatment of multiple sclerosis. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-clinical-investigation-medicinal-products-treatment-multiple-sclerosis_en-0.pdf"},{"issue":"11","key":"e_1_3_7_8_2","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1212\/01.WNL.0000096175.39831.21","article-title":"Effect of relapses on development of residual deficit in multiple sclerosis","volume":"61","author":"Lublin FD","year":"2003","unstructured":"Lublin FD , Baier M , Cutter G . Effect of relapses on development of residual deficit in multiple sclerosis. Neurology 61(11), 1528\u20131532 (2003).","journal-title":"Neurology"},{"issue":"1","key":"e_1_3_7_9_2","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.msard.2016.07.003","article-title":"Brain health: time matters in multiple sclerosis","volume":"9","author":"Giovannoni G","year":"2016","unstructured":"Giovannoni G , Butzkueven H , Dhib-Jalbut S Brain health: time matters in multiple sclerosis. Mult. Scler. Relat. Disord. 9(Suppl. 1), S5\u2013S48 (2016).","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"6","key":"e_1_3_7_10_2","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s00415-015-7986-y","article-title":"Optimizing treatment success in multiple sclerosis","volume":"263","author":"Ziemssen T","year":"2016","unstructured":"Ziemssen T , Derfuss T , De Stefano N Optimizing treatment success in multiple sclerosis. J. Neurol. 263(6), 1053\u20131065 (2016).","journal-title":"J. Neurol."},{"issue":"1","key":"e_1_3_7_11_2","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1212\/WNL.48.1.74","article-title":"Quality of life among persons with multiple sclerosis and their caregivers","volume":"48","author":"Aronson KJ","year":"1997","unstructured":"Aronson KJ . Quality of life among persons with multiple sclerosis and their caregivers. Neurology 48(1), 74\u201380 (1997).","journal-title":"Neurology"},{"issue":"6","key":"e_1_3_7_12_2","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1046\/j.1365-2710.2001.00377.x","article-title":"Prescribing for multiple sclerosis patients in general practice: a case-control study","volume":"26","author":"Tremlett HL","year":"2001","unstructured":"Tremlett HL , Luscombe DK , Wiles CM . Prescribing for multiple sclerosis patients in general practice: a case-control study. J. Clin. Pharm. Ther. 26(6), 437\u2013444 (2001).","journal-title":"J. Clin. Pharm. Ther."},{"issue":"4","key":"e_1_3_7_13_2","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s13167-019-00192-z","article-title":"Suggestions for improving the design of clinical trials in multiple sclerosis\u2014results of a systematic analysis of completed phase III trials","volume":"10","author":"Gehr S","year":"2019","unstructured":"Gehr S , Kaiser T , Kreutz R , Ludwig W-D , Paul F . Suggestions for improving the design of clinical trials in multiple sclerosis\u2014results of a systematic analysis of completed phase III trials. EPMA J. 10(4), 425\u2013436 (2019).","journal-title":"EPMA J."},{"key":"e_1_3_7_14_2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.4137\/PMC.S13213","article-title":"Multiple sclerosis: overview of disease-modifying agents","volume":"6","author":"Finkelsztejn A","year":"2014","unstructured":"Finkelsztejn A . Multiple sclerosis: overview of disease-modifying agents. Perspect. Medicin. Chem. 6, 65\u201372 (2014).","journal-title":"Perspect. Medicin. Chem."},{"key":"e_1_3_7_15_2","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1146\/annurev-med-052814-023415","article-title":"Novel agents for relapsing forms of multiple sclerosis","volume":"67","author":"Straus Farber R","year":"2016","unstructured":"Straus Farber R , Harel A , Lublin F . Novel agents for relapsing forms of multiple sclerosis. Annu. Rev. Med. 67, 309\u2013321 (2016).","journal-title":"Annu. Rev. Med."},{"issue":"6","key":"e_1_3_7_16_2","doi-asserted-by":"crossref","first-page":"530","DOI":"10.7861\/clinmedicine.17-6-530","article-title":"Multiple sclerosis, a treatable disease","volume":"17","author":"Doshi A","year":"2017","unstructured":"Doshi A , Chataway J . Multiple sclerosis, a treatable disease. Clin. Med. (Lond.) 17(6), 530\u2013536 (2017).","journal-title":"Clin. Med. (Lond.)"},{"key":"e_1_3_7_17_2","unstructured":"Gilenya [package insert]. Novartis Pharmaceuticals Corporation East Hanover NJ (2019). https:\/\/www.pharma.us.novartis.com\/sites\/www.pharma.us.novartis.com\/files\/gilenya.pdf"},{"issue":"18","key":"e_1_3_7_18_2","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1080\/14656566.2018.1540592","article-title":"Ozanimod for the treatment of relapsing remitting multiple sclerosis","volume":"19","author":"Rasche L","year":"2018","unstructured":"Rasche L , Paul F . Ozanimod for the treatment of relapsing remitting multiple sclerosis. Expert Opin. Pharmacother. 19(18), 2073\u20132086 (2018).","journal-title":"Expert Opin. Pharmacother."},{"key":"e_1_3_7_19_2","article-title":"Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial","author":"Cohen JA","year":"2019","unstructured":"Cohen JA , Comi G , Selmaj KW Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. Lancet Neurol. doi:10.1016\/S1474-4422(19)30238-8 (2019) (Epub ahead of print).","journal-title":"Lancet Neurol."},{"key":"e_1_3_7_20_2","article-title":"Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial","author":"Comi G","year":"2019","unstructured":"Comi G , Kappos L , Selmaj KW Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. Lancet Neurol. doi:10.1016\/S1474-4422(19)30239-X (2019) (Epub ahead of print).","journal-title":"Lancet Neurol."},{"issue":"2","key":"e_1_3_7_21_2","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/pds.3246","article-title":"Comparative effectiveness research using matching-adjusted indirect comparison: an application to treatment with guanfacine extended release or atomoxetine in children with attention-deficit\/hyperactivity disorder and comorbid oppositional defiant disorder","volume":"21","author":"Signorovitch J","year":"2012","unstructured":"Signorovitch J , Erder MH , Xie J Comparative effectiveness research using matching-adjusted indirect comparison: an application to treatment with guanfacine extended release or atomoxetine in children with attention-deficit\/hyperactivity disorder and comorbid oppositional defiant disorder. Pharmacoepidemiol. Drug Saf. 21(Suppl. 2), 130\u2013137 (2012).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"10","key":"e_1_3_7_22_2","doi-asserted-by":"crossref","first-page":"935","DOI":"10.2165\/11538370-000000000-00000","article-title":"Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept","volume":"28","author":"Signorovitch JE","year":"2010","unstructured":"Signorovitch JE , Wu EQ , Yu AP Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept. Pharmacoeconomics 28(10), 935\u2013945 (2010).","journal-title":"Pharmacoeconomics"},{"issue":"7","key":"e_1_3_7_23_2","doi-asserted-by":"crossref","first-page":"A750","DOI":"10.1016\/j.jval.2015.09.2902","article-title":"Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of relapsing-remitting multiple sclerosis [abstract PND10]","volume":"18","author":"Fox RJ","year":"2015","unstructured":"Fox RJ , Cutter G , Chan A Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of relapsing-remitting multiple sclerosis [abstract PND10]. Value Health 18(7), A750 (2015).","journal-title":"Value Health"},{"issue":"8","key":"e_1_3_7_24_2","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1080\/03007995.2019.1585779","article-title":"Estimating the comparative efficacy of cladribine tablets versus alternative disease modifying treatments in active relapsing-remitting multiple sclerosis: adjusting for patient characteristics using meta-regression and matching-adjusted indirect treatment comparison approaches","volume":"35","author":"Berardi A","year":"2019","unstructured":"Berardi A , Siddiqui MK , Treharne C , Harty G , Wong SL . Estimating the comparative efficacy of cladribine tablets versus alternative disease modifying treatments in active relapsing-remitting multiple sclerosis: adjusting for patient characteristics using meta-regression and matching-adjusted indirect treatment comparison approaches. Curr. Med. Res. Opin. 35(8), 1371\u20131378 (2019).","journal-title":"Curr. Med. Res. Opin."},{"issue":"3","key":"e_1_3_7_25_2","first-page":"981","article-title":"Ozanimod vs interferon \u03b2-1a: clinical and MRI results of RADIANCE part B - a 2-year phase 3 trial in relapsing multiple sclerosis [abstract 280]","volume":"23","author":"Cohen JA","year":"2017","unstructured":"Cohen JA , Comi G , Selmaj KW Ozanimod vs interferon \u03b2-1a: clinical and MRI results of RADIANCE part B - a 2-year phase 3 trial in relapsing multiple sclerosis [abstract 280]. Mult. Scler. J. 23(Suppl. 3), 981\u2013982 (2017).","journal-title":"Mult. Scler. J."},{"issue":"16","key":"e_1_3_7_26_2","doi-asserted-by":"crossref","first-page":"P6.344","DOI":"10.1212\/WNL.88.16_supplement.P6.344","article-title":"The RADIANCE and SUNBEAM phase 3 studies of ozanimod in relapsing multiple sclerosis: study design and baseline characteristics [abstract]","volume":"88","author":"Cree B","year":"2017","unstructured":"Cree B , Selmaj K , Kopicko J The RADIANCE and SUNBEAM phase 3 studies of ozanimod in relapsing multiple sclerosis: study design and baseline characteristics [abstract]. Neurology 88(Suppl. 16), P6.344 (2017).","journal-title":"Neurology"},{"issue":"3","key":"e_1_3_7_27_2","first-page":"73","article-title":"Ozanimod demonstrates efficacy and safety in a phase 3 trial of relapsing multiple sclerosis (SUNBEAM) [abstract 232]","volume":"23","author":"Comi G","year":"2017","unstructured":"Comi G , Kappos L , Selmaj KW Ozanimod demonstrates efficacy and safety in a phase 3 trial of relapsing multiple sclerosis (SUNBEAM) [abstract 232]. Mult. Scler. J. 23(Suppl. 3), 73\u201374 (2017).","journal-title":"Mult. Scler. J."},{"issue":"5","key":"e_1_3_7_28_2","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1056\/NEJMoa0907839","article-title":"Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis","volume":"362","author":"Cohen JA","year":"2010","unstructured":"Cohen JA , Barkhof F , Comi G Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N. Engl. J. Med. 362(5), 402\u2013415 (2010).","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"e_1_3_7_29_2","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis","volume":"362","author":"Kappos L","year":"2010","unstructured":"Kappos L , Radue EW , O'connor P A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N. Engl. J. Med. 362(5), 387\u2013401 (2010).","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"e_1_3_7_30_2","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S1474-4422(14)70049-3","article-title":"Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"13","author":"Calabresi PA","year":"2014","unstructured":"Calabresi PA , Radue EW , Goodin D Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 13(6), 545\u2013556 (2014).","journal-title":"Lancet Neurol."},{"issue":"5","key":"e_1_3_7_31_2","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.msard.2014.05.005","article-title":"First-dose effects of fingolimod: Pooled safety data from three phase 3 studies","volume":"3","author":"Dimarco JP","year":"2014","unstructured":"Dimarco JP , O'connor P , Cohen JA First-dose effects of fingolimod: Pooled safety data from three phase 3 studies. Mult. Scler. Relat. Disord. 3(5), 629\u2013638 (2014).","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"e_1_3_7_32_2","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman CH","year":"2011","unstructured":"Polman CH , Reingold SC , Banwell B Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann. Neurol. 69(2), 292\u2013302 (2011).","journal-title":"Ann. Neurol."},{"issue":"11","key":"e_1_3_7_33_2","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke JF","year":"1983","unstructured":"Kurtzke JF . Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33(11), 1444\u20131452 (1983).","journal-title":"Neurology"}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.2217\/cer-2019-0169","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T07:23:02Z","timestamp":1722324182000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.2217\/cer-2019-0169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["10.2217\/cer-2019-0169"],"URL":"https:\/\/doi.org\/10.2217\/cer-2019-0169","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3]]}}}